TITLE

Farming Without Ill Effects

AUTHOR(S)
RAGHUNATHAN, ANURADHA
PUB. DATE
October 2011
SOURCE
Forbes Asia;Oct2011, Vol. 7 Issue 12, p38
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article looks at the path followed by Dhirendra Kumar in starting a biotech company, Camson Biotechnologies Ltd., in Bangalore. It is given that the company's revenues hit 23 million dollars in March 2010, up 10 million dollars from 2008. It is given that the company is looking forward to enter into overseas markets where 100-acre holdings are common. The biggest challenges faced by the company to build a talented management team for high-quality execution and scale-up are also given.
ACCESSION #
66693386

 

Related Articles

  • Developing zero residue products is a big hurdle. OVHAL, MONALI // BioSpectrum;Feb2014, Vol. 12 Issue 2, p50 

    The article features Dhirendra Kumar, managing director of India-based Camson Biotechnologies company. Topics discussed include the achievements and research journey of Kumar, his leadership in the development and discovery of "zero-residue" products, and his perspective on the role of...

  • Camson Biotechnologies files patent for natural fertiliser.  // FRPT- Chemical Snapshot;8/31/2015, p23 

    The article reports that patents for a natural fertiliser, made from microbial extracts, has been filed by agri biotech firm, Camson Biotechnologies Ltd.

  • Natural Fertiliser to Replace Chemical Fertiliser.  // Chemical Engineering World;Aug2015, Vol. 50 Issue 8, p18 

    The article reports the filing of patents by Indian firm Camson BioTechnologies Ltd. as of August 2015 for its natural fertiliser product based on microbial extracts.

  • Money Raised By Biotech In 2013 vs. 2012.  // BioWorld Insight;3/25/2013, Vol. 21 Issue 13, p1 

    A chart is presented that compares the amount of money raised in the biotechnology industry in 2012 and 2013 through public offerings and private sectors.

  • Money Raised By Biotech: Jan. 1 - March 21, 2013.  // BioWorld Insight;3/25/2013, Vol. 21 Issue 13, p4 

    A pie chart is presented that shows the amount of money raised in the biotechnology industry between January-March 2013 through public offerings and private sectors.

  • Money Raised By Biotech: Jan. 1 - March 14, 2013.  // BioWorld Insight;3/18/2013, Vol. 21 Issue 12, p4 

    A pie diagram is presented which represents money raised by private and government biotech companies in the U.S. from January 1, 2013, to March 14, 2013.

  • IOMEDIA. Creamer, Matthew // Medical Marketing & Media;Jul2013, Vol. 48 Issue 7, p115 

    The article reports on the 40% increase of the annual revenue of the creative digital agency IOMEDIA Inc. in 2012. It notes that the growth was driven by the attainment of IOMEDIA of a deal with biotechnology corporations including Genentech Inc., Impax Laboratories Inc. and Baxter International...

  • By The Numbers: LARGEST BIOTECHNOLOGY COMPANIES.  // Modern Healthcare;8/2/2010, Vol. 40 Issue 31, p32 

    A chart is presented that lists the 20 largest biotechnology firms ranked by worldwide revenue in 2009, which includes Amgen, Genentech, and Biocon.

  • Earnings Roundup.  // BioWorld Today;2/24/2012, Vol. 23 Issue 37, p4 

    This section offers news briefs on earnings in the biopharmaceutical industry including the revenue growth of Auxilum Pharmaceuticals Inc. for the quarter that ended December 31, 2011, fourth-quarter sales growth of Dyax Corporation's Kalbitor drug, and an increase in the net income of Onyx...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics